Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- ABM Therapeutics Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT05831995
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Indiana University Simon and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- ABM Therapeutics Corporation
- Target Recruit Count
- 53
- Registration Number
- NCT04190628
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center (Northwestern University), Chicago, Illinois, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Stanford University School of Medicine, Stanford, California, United States
© Copyright 2024. All Rights Reserved by MedPath